Liquid protein formulations for injection comprising 1-butyl-3-methylimidazolium methanesulfonate and uses thereof
US9833513B2 · kind B2 · utility
3Cited by
62References
26Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 11, 2014 |
| Grant date | Dec 5, 2017 |
| Priority date | — |
| Expiry date | Jan 31, 2036 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02P20/54
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Concentrated, low-viscosity, low-volume liquid pharmaceutical formulations of proteins have been developed. Such formulations can be rapidly and conveniently administered by subcutaneous or intramuscular injection, rather than by lengthy intravenous infusion. These formulations include low-molecular-weight and/or high-molecular-weight proteins, such as mAbs, and viscosity-reducing ionic liquids.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.